We’re Picking Up Shares of This Social Media Powerhouse, Starting New Power Position
Plus, several other holdings we’re eyeballing and where some prudent portfolio management could be called for.
The AI Selloff Looks Like a Bear Trap. Follow the Bottleneck Instead.
One stop remains in our AI series, and it’s the one folks rarely think about.
The AI Boom Has an Electric Bill. Here’s Who Gets Paid.
AI needs more than Nvidia chips. Here are the companies ‘powering’ the AI buildout.
Weekly Roundup: The AI Trade Got Smacked. We’re Following the Data, Not the Fear
We put capital to work in two holdings, exited another and bumped up our price target for a long-time position.
Upside, Downside Movers in the Morning
Upside
– $LPCN +40% (Health Canada approves TLANDO for testosterone replacement therapy)
– $APUS +9.4% (extends a high-volume rally tied to the BlockAssure agreement to build and operate the AssureChain insurance network)
– $PENG +4.3% (Q4 beat and FY27 sales and EPS outlook topped prior guidance and Street expectations on accelerating AI-infrastructure demand)
– CNQ +1.6%, APA +1.2%, OXY +1.0%, COP +1.0% (oil producers rise as crude climbs back above $100 a barrel)
Downside
– $CRBU -42% (launches a strategic-alternatives review, discontinues two allogeneic CAR-T programs and plans substantial workforce reductions)
– $BULL -30% (bipartisan House panel report says structural China ties pose national-security and US-user-data risks)
– $STM -5.4%, $TER -3.0%, $ASML -3.0%, $AMAT -2.7%, $LRCX -3.0%, $MU -2.8% (chip stocks fall in the risk-off technology tape as oil-driven inflation concerns pressure rate-sensitive growth shares)
– $BMNR -5.0%, $CRCL -4.0%, $MSTR -3.8%, $COIN -3.1%, $HOOD -3.0% (crypto-linked stocks fall as digital-asset prices weaken)
– $AAOI -4.8%, $CIEN -3.8%, $MTSI -3.0%, $COHR -3.2%, $GLW -3.3% (AI-networking and optical winners pull back after sharp recent rallies as technology exposure is reduced)
– $DB -4.7%, $SAN -4.2%, $HSBC -3.9%, $NWG -3.5%, $BCS -3.3% (European-bank ADRs fall as oil-driven inflation and sovereign-bond stress deepen fiscal concerns, with UK lenders also facing budget-tax fears)
– $STZ -3.9% (quarter beat, but adjusted FY guidance was merely reiterated and beer depletions declined)
– $BE -3.8%, $CEG -3.5%, $EME -1.9% (AI-power and data-center infrastructure winners give back part of recent gains amid the broader risk-off rotation)
Continued Broadening Lifts S&P 500 to First Record Since August
The S&P notched its first record close since August on a continued broadening as Treasury yields remained subdued. The Nasdaq added a second straight record, but small-caps gave up an early gain.
Upside, Downside Movers in the Morning
Upside
– $MEDS +36% (preliminary September pharmacy revenue exceeded $1M, rising more than 66% from July)
– $ACN +17% (Q4 beat with $22.2B of bookings and stronger operating margins)
– $ABAT +13% (receives federal approval to export up to $100M of recycled black-mass material)
– $QSI +13% (no clear fresh catalyst identified; unusually large move on heavy premarket volume)
– $VICR +12% (raises Q3 sequential revenue-growth outlook to more than 30% from more than 20% on higher royalties)
– $GLOB +11%, $CTSH +7.5%, $INFY +8.1%, $EPAM +6.6% (IT-services names rise in read-through from ACN’s Q4 beat, strong bookings and margin performance)
– $INSG +9.6% (completes fixed-wireless-access acquisition expected to roughly double revenue and expand its global footprint)
– $IBM +5.7% (unveils a self-hosted enterprise AI model)
– $NU +5.6% (rebounds after clarifying it is not pursuing the reported UK digital-bank acquisition)
– $GLUE +4.8% (Phase 1 GFORCE-1 results showed normalization of key pathogenic drivers of cardiovascular disease)
– $RKLB +4.3% (signs its largest commercial launch agreement, covering 20 missions and lifting total backlog above 100 launches)
– $MKC +3.7% (Q3 profit and sales beat expectations as pricing offset softer volumes)
– $SNPS +3.7% (signs a multiyear silicon-IP and engineering-software agreement valued above $1B)
– $CEG +3.4% (signs a 20-year, 690-megawatt nuclear power agreement supporting more than $3B of infrastructure investment)
– $TARA +3.3% (updated 12-month Phase 2 ADVANCED-2 data showed durable responses in BCG-naïve bladder-cancer patients)
Downside
– $FHTX -43% (Phase 1 review leads to discontinuation of FHD-909 expansion and a related degrader program; workforce cut about 40%)
– $ANGO -16% (no clear fresh catalyst identified; unusually large, high-volume premarket decline)
– $LQDA -12% (federal court rules YUTREPIA infringed two pulmonary-hypertension patent claims)
– $ZELA -12% (Phase 3 obesity trial met its endpoints, but weight-loss efficacy fell short of investor expectations)
– $BGIN -10% (slides following first-half results)
– $IVA -10% (extends weakness following unaudited first-half results and corporate update)
– $FLOC -8.5% (no clear fresh catalyst identified; unusually large, liquid premarket decline)
– $ENTX -6.4% (no clear fresh catalyst identified after healthcare and company-news checks)
Just Barely Head and Shoulders Above the 50-Day Moving Average
Let’s chat about market sentiment, that pesky head and shoulders top, and moving averages.